Laidlaw Capital Markets is pleased to have Lead Managed aTyr Pharma's (LIFE) $86,250,000. Offering alongside Piper Sandler and RBC. Read Article: https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-pricing-75-million-public-offering-common
About Stephen DeLormeThis author has not yet filled in any details.
So far Stephen DeLorme has created 10 blog entries.
Laidlaw Capital Markets is pleased to have acted as Sole Book-Runner on the $10,000,000 Follow-On Offering for BioSig Technologes (BSGM).Stephen DeLorme2021-07-12T10:07:55+00:00
The Laidlaw Capital Markets team is pleased to announce our role as Sole Book-Runner and the pricing of a $10,000,000 Follow-on Offering for BioSig Technologies (BSGM). We are proud to have raised approximately $40,000,000 for BioSig over the course of our decade long relationship and look forward to watch the company continue to execute. Read Read More...
Laidlaw Capital Markets is pleased to have acted as Co-Manager on the $125,000,000 Follow-On Offering for Aldeyra Therapeutics.Stephen DeLorme2021-04-30T19:38:18+00:00
Laidlaw Capital Markets is pleased to Co-Manage Aldeyra Therapeutics $125,000,000 financing alongside Jefferies and SVB Leerink. Over $300 million raised together since 2014, helping fuel Aldeyra’s excellent execution in developing its pipeline and delivering results for patients and investors. Read Article: Aldeyra Therapeutics, Inc. Announces Pricing of $125 Million Public Offering of Common Stock
Voltron Therapeutics, Inc. Announces Positive Data from Animal Testing of Self-Assembling Vaccine in the Fight Against COVID-19Stephen DeLorme2021-03-30T21:49:51+00:00
From globenewswire.com: Voltron Therapeutics, Inc. today announced positive data from its second set of preclinical animal testing of its HaloVax™ Self-Assembling Vaccine (SAV) against COVID-19. This study investigated an updated construct, based on initial testing as well as recent scientific developments, in order to identify the best balance of immune responses for prevention of this Read More...
Laidlaw Capital Markets is pleased to have acted as Co-Manager on the $25,000,000 Follow-On Offering for iCAD Inc.Stephen DeLorme2021-03-15T16:01:03+00:00
The Team at Laidlaw Capital Markets is pleased to have acted as the Co-Manager on the $25,000,000 Follow-On Offering for iCAD, Inc. (ICAD). iCAD has been a partner for years now and we are excited for their continued success. Click the link below for additional information: iCAD Announces Closing of $25.0 Million Public Offering of Read More...
Laidlaw Venture Partners Portfolio Company, AerWave Medical, Inc., Closes $4,000,000 Series A Financing Round.Stephen DeLorme2021-02-24T11:31:02+00:00
From globenewswire.com: Laidlaw Venture Partners (“LVP”), the venture capital arm of Laidlaw & Company (UK) Ltd., today announced the successful closing of a $4 million Series A financing round for its portfolio company AerWave. Click the link below for additional information: AerWave Medical Closes Series A Financing
Laidlaw Capital Markets served as Financial Advisor on the $115,000,000 Follow-On Offering for EyePoint PharmaceuticalsStephen DeLorme2021-02-10T14:11:41+00:00
The Team at Laidlaw Capital Markets is pleased to have acted as Financial Advisor on the $115,000,000 Follow-On Offering, alongside Guggenheim and Cowen. This is the third transaction Laidlaw has been a part of with the company and we look forward to their continued success. See full Press Release
Laidlaw Venture Partners Portfolio Company Voltron Therapeutics, Inc. Names Anthony Zook, Former CEO of AstraZeneca North America, Executive Chairman.Stephen DeLorme2021-01-28T21:15:30+00:00
From globenewswire.com: Voltron Therapeutics, Inc. today announced that it has appointed life science veteran Anthony Zook Executive Chairman of its Board of Directors. As a global industry leader, Mr. Zook brings years of strategic experience to Voltron Therapeutics and is expected to be instrumental in the further development and eventual commercialization of its Self Assembling Read More...
Laidlaw Capital Markets is pleased to have acted as the Sole Book-Runner on the $14,375,000 Follow-On Offering for Evoke Pharma (EVOK). Evoke has been a partner for years now and we are excited for their continued progress as a commercial stage company. https://evokepharmainc.gcs-web.com/news-releases/news-release-details/evoke-pharma-announces-pricing-public-offering-common-stock-0
Laidlaw Venture Partners portfolio company, Amesite (Nasdaq Ticker, AMST), CEO Ann Marie Sastry on Fox Business News todayStephen DeLorme2020-12-04T18:30:15+00:00
From prnewswire.com: Amesite Inc. (Nasdaq: AMST), an artificial intelligence software company providing online learning ecosystems for business, higher education, and K-12, announced today its CEO, Dr. Ann Marie Sastry, is scheduled to appear today on Fox Business Network's CAVUTO Coast to Coast which airs weekdays at Noon ET. Please click the link below for more information: Amesite CEO Dr. Ann Marie Read More...